Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-20T04:41:35.969Z Has data issue: false hasContentIssue false
  • English
  • Français

A Comparative Double Blind Trial of Pimozide and Fluphenazine in Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

P. A. Morris ,
D. H. MacKenzie  and
H. C. Masheter
P. A. Morris
Affiliation:
Kingsway Hospital, Derby, DE3 3LZ.
D. H. MacKenzie
Affiliation:
Kingsway Hospital, Derby, DE3, 3LZ.
H. C. Masheter
Affiliation:
Janssen Pharmaceuticals, Saunderton, High Wycombe, Bucks
Get access Rights & Permissions [Opens in a new window]

Extract

Pimozide is a new neuroleptic drug and is chemically described as bis-para-fluoro-phenyl-butylpiperidine. It is active after oral administration, with a 24 hour duration of action and a peak effect lasting four to six hours (1). Superiority over placebo has been demonstrated by Brugmans (2).

Type
Abstract
Information
The British Journal of Psychiatry , Volume 117 , Issue 541 , December 1970 , pp. 683 - 684
Copyright
Copyright © The Royal College of Psychiatrists, 1970 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Janssen, P. A. J., Niemeoeers, C. J. E., Schellekens, K. H. L., Dresse, A., Lenaerts, F. M., Pinchard, A., Schaper, W. K. A., Van Nueten, J. M., and Verbruggen, F. J. (1969). ‘Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug.’ Arzneim.-Forsch. (Drug Res.), 18, 261.Google Scholar
2 Brugmans, J. (1968). ‘A multicentric clinical evaluation of pimozide.’ Acta neurol. psychiat. Belg., 68, 875.Google ScholarPubMed
3 Gorham, D. R., and Overall, J. E. (1960). J. nerv. ment. Dis., 132, 158.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.